 | • レポートコード：MRC2303E114 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、220ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療機器 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料は、2021年に2,850.24百万ドルであった世界の治療薬モニタリング市場規模が、2022年に3,284.39百万ドルになり、2027年まで年平均15.69%で成長して6,837.21百万ドルに到達すると予想しています。本レポートでは、治療薬モニタリングの世界市場を広く調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（消耗品、データ管理サービス、機器）分析、技術別（クロマトグラフィー-MS、イムノアッセイ、プロテオミクス）分析、薬物クラス別（抗不整脈薬、抗生物質、抗てんかん薬、気管支拡張薬、免疫抑制剤）分析、エンドユーザー別（病院研究室、民間研究室）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、参入企業情報として、Abbott Laboratories、Agilent Technologies, Inc.、apDia Group、ARK Diagnostics, Inc.、Bio-Rad Laboratories, Inc.、bioMérieux SA、Bühlmann Laboratories AG、Cambridge Life Sciences Limited、Chromsystems Instruments & Chemicals GmbH、Danaher Corporation、DiaSystem Scandinavia AB、Eagle Biosciences, Inc.、Exagen Inc.、F. Hoffmann-La Roche AG、Fujirebio Europe N.V.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の治療薬モニタリング市場規模：製品別 - 消耗品の市場規模 - データ管理サービスの市場規模 - 機器の市場規模 ・世界の治療薬モニタリング市場規模：技術別 - クロマトグラフィー-MS技術の市場規模 - イムノアッセイ技術の市場規模 - プロテオミクス技術の市場規模 ・世界の治療薬モニタリング市場規模：薬物クラス別 - 抗不整脈薬の市場規模 - 抗生物質の市場規模 - 抗てんかん薬の市場規模 - 気管支拡張薬の市場規模 - 免疫抑制剤の市場規模 ・世界の治療薬モニタリング市場規模：エンドユーザー別 - 病院研究室における市場規模 -民間研究室における市場規模 ・世界の治療薬モニタリング市場規模：地域別 - 南北アメリカの治療薬モニタリング市場規模 アメリカの治療薬モニタリング市場規模 カナダの治療薬モニタリング市場規模 ブラジルの治療薬モニタリング市場規模 ... - アジア太平洋の治療薬モニタリング市場規模 日本の治療薬モニタリング市場規模 中国の治療薬モニタリング市場規模 インドの治療薬モニタリング市場規模 韓国の治療薬モニタリング市場規模 台湾の治療薬モニタリング市場規模 ... -ヨーロッパ/中東/アフリカの治療薬モニタリング市場規模 イギリスの治療薬モニタリング市場規模 ドイツの治療薬モニタリング市場規模 フランスの治療薬モニタリング市場規模 ロシアの治療薬モニタリング市場規模 ... -その他地域の治療薬モニタリング市場規模 ・競争状況 ・企業情報 |
The Global Therapeutic Drug Monitoring Market size was estimated at USD 2,850.24 million in 2021 and expected to reach USD 3,284.39 million in 2022, and is projected to grow at a CAGR 15.69% to reach USD 6,837.21 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Therapeutic Drug Monitoring to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Consumables, Data Management Services, and Equipment. The Equipment is further studied across Chromatography & MS Detectors, Clinical Chemistry Analyzers, and Immunoassay Analyzers.
Based on Technology, the market was studied across Chromatography-MS, Immunoassays, and Proteomic Technologies. The Chromatography-MS is further studied across GC-MS and LC-MS. The Immunoassays is further studied across Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, and Radioimmunoassays.
Based on Drug Class, the market was studied across Antiarrhythmic Drugs, Antibiotic Drugs, Antiepileptic Drugs, Bronchodilator Drugs, Immunosuppressant Drugs, and Psychoactive Drugs.
Based on End-User, the market was studied across Hospital Labs and Private Labs.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Arkansas, California, Florida, Illinois, Kentucky, Minnesota, New Jersey, New Mexico, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Therapeutic Drug Monitoring market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Therapeutic Drug Monitoring Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Therapeutic Drug Monitoring Market, including Abbott Laboratories, Agilent Technologies, Inc., apDia Group, ARK Diagnostics, Inc., Bio-Rad Laboratories, Inc., bioMérieux SA, Bühlmann Laboratories AG, Cambridge Life Sciences Limited, Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, DiaSystem Scandinavia AB, Eagle Biosciences, Inc., Exagen Inc., F. Hoffmann-La Roche AG, Fujirebio Europe N.V., Grifols, S.A., Merck KGaA, Myriad Genetics, Inc., R-Biopharm AG, Randox Laboratories, Ltd., Sekisui Chemical Co Ltd., Siemens Healthineers AG, Tecan Trading AG, Theradiag, and Thermo Fisher Scientific, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Therapeutic Drug Monitoring Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Therapeutic Drug Monitoring Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Therapeutic Drug Monitoring Market?
4. What is the competitive strategic window for opportunities in the Global Therapeutic Drug Monitoring Market?
5. What are the technology trends and regulatory frameworks in the Global Therapeutic Drug Monitoring Market?
6. What is the market share of the leading vendors in the Global Therapeutic Drug Monitoring Market?
7. What modes and strategic moves are considered suitable for entering the Global Therapeutic Drug Monitoring Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased Demand for Personalized Medicine
5.1.1.2. Rising Adoption of Therapeutic Drug Monitoring Across Various Therapeutic Fields
5.1.1.3. Growing Use and Importance in Patients with Solid Organ Transplantation
5.1.2. Restraints
5.1.2.1. Inadequate Reimbursement Policies
5.1.2.2. Need of High Capital Investments
5.1.3. Opportunities
5.1.3.1. Future Perspectives of Therapeutic Drug Monitoring in Developing Nations
5.1.3.2. Developments in Immunoassay and Other Therapeutic Drug Monitoring Technologies
5.1.4. Challenges
5.1.4.1. Clinical Challenges and Limited Availability of Skilled Laboratory Technicians
5.2. Cumulative Impact of COVID-19
6. Therapeutic Drug Monitoring Market, by Product
6.1. Introduction
6.2. Consumables
6.3. Data Management Services
6.4. Equipment
6.5.1. Chromatography & MS Detectors
6.5.2. Clinical Chemistry Analyzers
6.5.3. Immunoassay Analyzers
7. Therapeutic Drug Monitoring Market, by Technology
7.1. Introduction
7.2. Chromatography-MS
7.3.1. GC-MS
7.3.2. LC-MS
7.3. Immunoassays
7.4.1. Chemiluminescence Immunoassays
7.4.2. Colorimetric Immunoassays
7.4.3. Fluorescence Immunoassays
7.4.4. Radioimmunoassays
7.4. Proteomic Technologies
8. Therapeutic Drug Monitoring Market, by Drug Class
8.1. Introduction
8.2. Antiarrhythmic Drugs
8.3. Antibiotic Drugs
8.4. Antiepileptic Drugs
8.5. Bronchodilator Drugs
8.6. Immunosuppressant Drugs
8.7. Psychoactive Drugs
9. Therapeutic Drug Monitoring Market, by End-User
9.1. Introduction
9.2. Hospital Labs
9.3. Private Labs
10. Americas Therapeutic Drug Monitoring Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Therapeutic Drug Monitoring Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Therapeutic Drug Monitoring Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Agilent Technologies, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. apDia Group
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. ARK Diagnostics, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Bio-Rad Laboratories, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. bioMérieux SA
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Bühlmann Laboratories AG
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Cambridge Life Sciences Limited
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Chromsystems Instruments & Chemicals GmbH
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Danaher Corporation
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. DiaSystem Scandinavia AB
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Eagle Biosciences, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Exagen Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. F. Hoffmann-La Roche AG
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Fujirebio Europe N.V.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Grifols, S.A.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Merck KGaA
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Myriad Genetics, Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. R-Biopharm AG
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Randox Laboratories, Ltd.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Sekisui Chemical Co Ltd.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Siemens Healthineers AG
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Tecan Trading AG
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Theradiag
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Thermo Fisher Scientific, Inc.
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing